International Clinical Trial: A Prospective, Single-Center, Exploratory Study on the Efficacy and Safety of Ultra-Low-Dose Decitabine Combined with Escalating-Dose Donor Lymphocyte Infusion for Post-Transplant Relapse Prevention in Patients with Bi-allelic TP53 Mutated Myelodysplastic Syndromes

Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500114629) titled 'A Prospective, Single-Center, Exploratory Study on the Efficacy and Safety of Ultra-Low-Dose Decitabine Combined with Escalating-Dose Donor Lymphocyte Infusion for Post-Transplant Relapse Prevention in Patients with Bi-allelic TP53 Mutated Myelodysplastic Syndromes' on Dec. 16, 2025.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: The FIrst Affiliated Hospital, College of Medicine, Zhejiang University

Condition: Myelodysplastic Syndromes

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2025-12-25

Target Sample Size: Experimental group:32;

Countries of ...